Metabolic pathways fueling the suppressive activity of myeloid-derived suppressor cells.

Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Original Publication: [Lausanne : Frontiers Research Foundation]

Myeloid-Derived Suppressor Cells*/immunology ; Myeloid-Derived Suppressor Cells*/metabolism ; Metabolic Networks and Pathways* ; Neoplasms*/immunology ; Neoplasms*/metabolism; Humans ; Animals ; Glycolysis ; Immune Tolerance ; Tumor Microenvironment/immunology

Myeloid-derived suppressor cells (MDSC) are considered an aberrant population of immature myeloid cells that have attracted considerable attention in recent years due to their potent immunosuppressive activity. These cells are typically absent or present in very low numbers in healthy individuals but become abundant under pathological conditions such as chronic infection, chronic inflammation and cancer. The immunosuppressive activity of MDSC helps to control excessive immune responses that might otherwise lead to tissue damage. This same immunosuppressive activity can be detrimental, particularly in cancer and chronic infection. In the cancer setting, tumors can secrete factors that promote the expansion and recruitment of MDSC, thereby creating a local environment that favors tumor progression by inhibiting the effective immune responses against cancer cells. This has made MDSC a target of interest in cancer therapy, with researchers exploring strategies to inhibit their function or reduce their numbers to improve the efficacy of cancer immunotherapies. In the context of chronic infections, MDSC can lead to persistent infections by suppressing protective immune responses thereby preventing the clearance of pathogens. Therefore, targeting MDSC may provide a novel approach to improve pathogen clearance during chronic infections. Ongoing research on MDSC aims to elucidate the exact processes behind their expansion, recruitment, activation and suppressive mechanisms. In this context, it is becoming increasingly clear that the metabolism of MDSC is closely linked to their immunosuppressive function. For example, MDSC exhibit high rates of glycolysis, which not only provides energy but also generates metabolites that facilitate their immunosuppressive activity. In addition, fatty acid metabolic pathways, such as fatty acid oxidation (FAO), have been implicated in the regulation of MDSC suppressive activity. Furthermore, amino acid metabolism, particularly arginine metabolism mediated by enzymes such as arginase-1, plays a critical role in MDSC-mediated immunosuppression. In this review, we discuss the metabolic signature of MDSC and highlight the therapeutic implications of targeting MDSC metabolism as a novel approach to modulate their immunosuppressive functions.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Goldmann and Medina.)

Invest New Drugs. 2019 Aug;37(4):711-721. (PMID: 30569245)
Curr Oncol. 2022 Apr 24;29(5):3044-3060. (PMID: 35621637)
Nature. 2019 May;569(7754):73-78. (PMID: 30996346)
J Immunother Cancer. 2023 May;11(5):. (PMID: 37217243)
J Immunol Res. 2022 Jun 12;2022:3119375. (PMID: 35733921)
Int J Mol Sci. 2021 Aug 21;22(16):. (PMID: 34445735)
Pharmaceutics. 2023 Feb 02;15(2):. (PMID: 36839825)
Cancer Immunol Res. 2020 Apr;8(4):465-478. (PMID: 32047024)
Crit Rev Biochem Mol Biol. 2014 Jan-Feb;49(1):1-15. (PMID: 24099156)
J Clin Invest. 2015 Sep;125(9):3356-64. (PMID: 26168215)
Cancer Res. 2007 May 1;67(9):4507-13. (PMID: 17483367)
Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211036304. (PMID: 34350796)
Front Immunol. 2020 Jul 30;11:1680. (PMID: 32849585)
Front Immunol. 2024 Jan 08;14:1334205. (PMID: 38259490)
Cell Metab. 2018 Nov 6;28(5):669-670. (PMID: 30403984)
Cell Death Differ. 2008 Apr;15(4):621-7. (PMID: 18259201)
Adv Cancer Res. 2015;128:95-139. (PMID: 26216631)
J Infect Dis. 2017 Dec 12;216(11):1444-1451. (PMID: 29029332)
Pharmacol Ther. 2019 Apr;196:105-116. (PMID: 30521884)
Front Immunol. 2018 Jan 04;8:1895. (PMID: 29354120)
J Immunol. 2008 Oct 1;181(7):4666-75. (PMID: 18802069)
Immunity. 2015 Mar 17;42(3):419-30. (PMID: 25786174)
J Immunol. 2006 Jan 1;176(1):284-90. (PMID: 16365420)
J Mol Cell Biol. 2013 Jun;5(3):207-9. (PMID: 23532593)
Nat Rev Immunol. 2005 Aug;5(8):641-54. (PMID: 16056256)
J Clin Invest. 2010 Feb;120(2):457-71. (PMID: 20093776)
J Immunol. 2007 Nov 1;179(9):5999-6008. (PMID: 17947673)
Cancer Immunol Immunother. 2016 Feb;65(2):161-9. (PMID: 26728481)
Nature. 2008 May 1;453(7191):65-71. (PMID: 18362915)
Nat Rev Drug Discov. 2014 Jun;13(6):433-44. (PMID: 24833295)
Clin Cancer Res. 2019 Mar 1;25(5):1462-1471. (PMID: 30377198)
Cell Metab. 2008 Jan;7(1):11-20. (PMID: 18177721)
Signal Transduct Target Ther. 2021 Oct 7;6(1):362. (PMID: 34620838)
Cell Mol Life Sci. 2023 Jul 22;80(8):221. (PMID: 37480485)
Annu Rev Physiol. 2016;78:23-44. (PMID: 26474213)
Nat Rev Cancer. 2002 Jan;2(1):38-47. (PMID: 11902584)
Cells. 2023 Mar 03;12(5):. (PMID: 36899934)
Cell. 2018 Feb 8;172(4):825-840.e18. (PMID: 29336888)
Immunity. 2013 Apr 18;38(4):633-43. (PMID: 23601682)
Immunol Rev. 2023 Mar;314(1):427-441. (PMID: 36326284)
Front Immunol. 2019 Jul 03;10:1462. (PMID: 31333642)
Nat Rev Immunol. 2021 Aug;21(8):485-498. (PMID: 33526920)
J Immunol. 2013 Apr 1;190(7):3783-97. (PMID: 23440412)
Cell Immunol. 2021 Jan;359:104254. (PMID: 33296753)
Int J Biochem Cell Biol. 2004 Aug;36(8):1374-9. (PMID: 15147715)
J Clin Invest. 2020 Jul 1;130(7):3865-3884. (PMID: 32324593)
Biochem Biophys Res Commun. 2012 Sep 7;425(4):724-9. (PMID: 22885179)
Eur J Cancer. 2017 Aug;81:116-129. (PMID: 28623775)
Prog Lipid Res. 1995;34(4):267-342. (PMID: 8685242)
Cancer Immunol Immunother. 2014 Aug;63(8):847-57. (PMID: 24878890)
Front Immunol. 2019 Sep 20;10:2099. (PMID: 31616403)
Nat Rev Immunol. 2024 Aug;24(8):596-613. (PMID: 38467802)
Cell Mol Immunol. 2018 Jun;15(6):618-629. (PMID: 28287112)
Science. 2009 May 22;324(5930):1029-33. (PMID: 19460998)
Immunity. 2019 Feb 19;50(2):288-301. (PMID: 30784577)
Cancer Immunol Res. 2015 Nov;3(11):1236-47. (PMID: 26025381)
Front Immunol. 2021 Aug 31;12:661323. (PMID: 34531850)
Immunity. 2021 May 11;54(5):875-884. (PMID: 33979585)
Sci Rep. 2017 Aug 29;7(1):9850. (PMID: 28852166)
J Exp Med. 2010 Oct 25;207(11):2439-53. (PMID: 20876310)
Nat Rev Cancer. 2017 Dec;17(12):709-724. (PMID: 29059149)
J Biol Chem. 2002 Jun 14;277(24):21123-9. (PMID: 11950832)
Nat Rev Nephrol. 2022 Sep;18(9):573-587. (PMID: 35726016)
Nat Rev Clin Oncol. 2020 Oct;17(10):611-629. (PMID: 32514148)
Acta Biochim Biophys Sin (Shanghai). 2013 Jan;45(1):51-60. (PMID: 23257294)
Annu Rev Immunol. 2014;32:609-34. (PMID: 24655299)
Cell. 2017 May 4;169(4):570-586. (PMID: 28475890)
Annu Rev Nutr. 2014;34:1-30. (PMID: 24819326)
J Immunol. 2010 Sep 15;185(6):3190-8. (PMID: 20720200)
Curr Opin Immunol. 2018 Apr;51:68-75. (PMID: 29544121)
Science. 2013 Oct 11;342(6155):1242454. (PMID: 24115444)
Blood. 2007 Feb 15;109(4):1568-73. (PMID: 17023580)
J Innate Immun. 2018;10(5-6):407-413. (PMID: 29945134)
Front Immunol. 2018 Jun 11;9:1310. (PMID: 29942309)
J Leukoc Biol. 2019 May;105(5):857-872. (PMID: 30480847)
IUBMB Life. 2012 Jan;64(1):1-9. (PMID: 22131303)
J Biol Chem. 1996 Jul 26;271(30):17771-8. (PMID: 8663540)
Front Immunol. 2020 Jul 22;11:1371. (PMID: 32793192)
Cell Metab. 2018 Feb 6;27(2):281-298. (PMID: 29129785)
J Clin Invest. 2013 Oct;123(10):4464-78. (PMID: 24091328)
Cancer Res. 2014 Feb 1;74(3):727-37. (PMID: 24351289)
JAMA Oncol. 2021 Jan 01;7(1):61-69. (PMID: 33151286)
Eur J Immunol. 2014 Nov;44(11):3307-19. (PMID: 25113564)
Nat Rev Immunol. 2020 Nov;20(11):651-668. (PMID: 32433532)
Biochim Biophys Acta. 2016 Oct;1863(10):2422-35. (PMID: 26828774)
Transplantation. 2007 Jul 15;84(1 Suppl):S17-20. (PMID: 17632406)
Mol Med. 2011 Mar-Apr;17(3-4):281-92. (PMID: 21085745)
Oncogenesis. 2018 Jan 24;7(1):10. (PMID: 29362402)
Cancer Biol Ther. 2018 Aug 3;19(8):695-705. (PMID: 29621426)
J Exp Med. 1999 May 3;189(9):1363-72. (PMID: 10224276)
Nat Rev Drug Discov. 2019 May;18(5):379-401. (PMID: 30760888)
Cell Rep. 2020 Dec 15;33(11):108500. (PMID: 33326785)
Front Cell Infect Microbiol. 2016 Mar 31;6:37. (PMID: 27066459)
Front Cell Dev Biol. 2021 Jul 14;9:707198. (PMID: 34336860)
Blood. 2011 Nov 17;118(20):5498-505. (PMID: 21972293)
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2611-6. (PMID: 16477023)
Nat Immunol. 2018 Feb;19(2):108-119. (PMID: 29348500)
BMC Cell Biol. 2012 Jul 04;13:18. (PMID: 22762146)
Nat Commun. 2016 Jul 06;7:12150. (PMID: 27381735)
Front Immunol. 2022 Oct 11;13:961805. (PMID: 36304470)
Immunol Rev. 2012 Sep;249(1):27-42. (PMID: 22889213)
J Exp Med. 2013 Jul 1;210(7):1389-402. (PMID: 23752227)
IUBMB Life. 2012 Feb;64(2):109-19. (PMID: 22162139)
Immunol Rev. 2012 Sep;249(1):14-26. (PMID: 22889212)
Semin Cancer Biol. 2009 Feb;19(1):12-6. (PMID: 19114105)
J Clin Invest. 2023 Jul 3;133(13):. (PMID: 37395271)
J Innate Immun. 2022;14(3):257-274. (PMID: 34763332)
PLoS Pathog. 2017 Sep 11;13(9):e1006616. (PMID: 28892492)
Cancer Res. 2004 Aug 15;64(16):5839-49. (PMID: 15313928)
Oncoimmunology. 2017 Jun 30;6(10):e1344804. (PMID: 29123954)
Br J Cancer. 2022 Dec;127(12):2175-2185. (PMID: 36266575)
Exp Mol Med. 2024 Mar;56(3):549-558. (PMID: 38443597)
Clin Colorectal Cancer. 2019 Mar;18(1):e8-e19. (PMID: 30293873)
Cancer Res. 2007 Jan 1;67(1):425; author reply 426. (PMID: 17210725)
J Immunother Cancer. 2014 Feb 18;2:3. (PMID: 24829760)

Keywords: immunosuppression; infection; metabolic reprogramming; metabolism; myeloid-derived suppressor cells; tumor

Date Created: 20241113 Date Completed: 20241113 Latest Revision: 20241114

20241115

PMC11554506

10.3389/fimmu.2024.1461455

39534601